Clinical Trials Logo

Filter by:
NCT ID: NCT04687072 Completed - Clinical trials for Primary Immune Thrombocytopenia

A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

ADVANCE SC
Start date: December 11, 2020
Phase: Phase 3
Study type: Interventional

This is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group trial to evaluate the efficacy, safety, and effect on QoL/PRO of efgartigimod PH20 SC treatment in adult patients with primary ITP.

NCT ID: NCT04686747 Completed - Colorectal Cancer Clinical Trials

COVID - 19 and Advanced Gastro-intestinal Cancer Treatment

COVID - AGICT
Start date: January 1, 2021
Phase:
Study type: Observational

A multicenter Italian retrospective study on COVID-19 pandemic condition and advanced Gastro - Intestinal Cancer. Are in Italy increased the new diagnosis of GI cancer in advanced stage in the 2020 compared with 2019, as a consequence of COVID-19?

NCT ID: NCT04686721 Recruiting - Tracheal Stenosis Clinical Trials

Observational Study for the Evaluation of Tracheal Stenosis in COVID-19 Patients

TS1
Start date: December 20, 2020
Phase:
Study type: Observational [Patient Registry]

Define the actual incidence of tracheal stenosis in patients who underwent either prolonged intubation or tracheostomy and to compare incidence, clinical course and outcome between COVID-19 and non-COVID-19 patients.

NCT ID: NCT04686305 Recruiting - Clinical trials for Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

DL03
Start date: March 9, 2021
Phase: Phase 1
Study type: Interventional

DESTINY-Lung03 will investigate the safety and tolerability of trastuzumab deruxtecan in combination with Immunotherapy Agents with and without chemotherapy in patients with HER2 over-expressing non-small cell lung cancer. The efficacy will be also analyzed as a secondary endpoint.

NCT ID: NCT04686136 Active, not recruiting - Chronic Migraine Clinical Trials

A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

Start date: February 19, 2021
Phase: Phase 3
Study type: Interventional

This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic or Episodic Migraine

NCT ID: NCT04685538 Completed - Cataract Clinical Trials

Chloroprocaine 3% Gel Eye Drop as Topical Anestheticsin Phacoemulsification.

Start date: September 9, 2020
Phase: Phase 3
Study type: Interventional

Randomized clinical trial, multicenter, two-armed, to investigate and compare the clinical efficacy of chloroprocaine 3% gel and tetracaine 0.5% eye drop as topical anestheticsin phacoemulsification. This prospective, observer masked, randomised, controlled, equivalence phase 3 study will be conducted in approximately 4 European Countries. Sintetica intends to perform a phase 3 study on patients undergoing cataract surgery to assess the safety and efficacy of topical anaesthesia using chloroprocaine gel.

NCT ID: NCT04685447 Completed - Covid19 Clinical Trials

Effects of Different Dialysis Strategies on Inflammation in COVID-19 Maintenance Hemodialysis Patients

Start date: March 16, 2020
Phase: N/A
Study type: Interventional

In the course of Coronavirus Disease-19 (COVID-19) uncontrolled inflammation has been related to disease severity and unfavorable outcomes. Here, the investigators study the longitudinal changes of pro- and anti-inflammatory markers in a population of patients undergoing maintenance hemodialysis (HD) affected by COVID-19, evaluating the potential modulating effects of two different dialysis approaches

NCT ID: NCT04685135 Active, not recruiting - Clinical trials for Metastatic Non Small Cell Lung Cancer

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

KRYSTAL-12
Start date: April 1, 2021
Phase: Phase 3
Study type: Interventional

This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.

NCT ID: NCT04684940 Recruiting - Clinical trials for Hemophilia A With Inhibitor

Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors

GENEr8-INH
Start date: December 10, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This Phase I/II clinical study will evaluate the safety and efficacy of valoctocogene roxaparvovec in patients with severe haemophilia A and inhibitors to FVIII. Part A of the study will involve subjects who have active inhibitors to FVIII, and Part B involving subjects with a prior history of inhibitors.

NCT ID: NCT04684511 Terminated - Clinical trials for Hemophilic Arthropathy

Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy

RESET-HA
Start date: June 2, 2021
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized, double-blind study to evaluate the efficacy and safety of TRM-201 (rofecoxib) versus Placebo in the treatment of patients with hemophilic arthropathy (HA) over a 12-week period (Part I) that is followed by a year-long (52 week) open-label extension (Part II) to further evaluate the safety and maintenance of efficacy of TRM-201.